News
-
-
2026-01-26
突破递送边界，共启行业新篇 ——引正基因与宜明生物达成战略合作
2026年1 月26日，引正基因 (GenEditBio) 今日宣布与宜明生物正式达成战略合作，共同开发新一代LNP体外递送技术。
more >
-
2026-01-05
GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy
GenEditBio receives FDA IND clearance to initiate a multicenter Phase 1/2 trial in the U.S. for its lead in vivo genome-editing therapy GEB-101 for TGFBI corneal dystrophy
more >
-
2025-11-24
GenEditBio and ToolGen Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics
GenEditBio announced it has entered into a strategic cross-license agreement with ToolGen Inc. from Korea to jointly accelerate the development of innovative
genome-editing therapeutics for diseases with unmet needs, including GEB-200 on atherosclerotic cardiovascular disease.more >
-
-
-
Copyright © 2025 GenEditBio
Provide affordable precision DNA surgery for genetic diseases with unmet needs
Business Contact bd@geneditbio.com
Media Contact geb.media@geneditbio.com
HONG KONG Unit 101-102, Building 6W, 6 Science Park West Avenue, Hong Kong hkoffice@geneditbio.com
BEIJING 4/F, Building 29, Yard 18, Kechuang 13th St, VPark, Beijing
